Validation of the effectiveness of a self-sampling high-risk human papillomavirus (hrHPV) test through the Web: a prospective study using questionnaires in hrHPV-positive women on the possibility of motivating them to receive cervical cancer screening and its usefulness as a CIN 2 or worse detection tool

Validation of the effectiveness of a self-sampling high-risk human papillomavirus (hrHPV) test through the Web: a prospective study using questionnaires in hrHPV-positive women on the possibility of motivating them to receive cervical cancer screening and its usefulness as a CIN 2 or worse detection tool - A validation study of the effectiveness of a self-sampling high-risk human papillomavirus test through the Web for cervical cancer screening (VEST study)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045183

Enrollment

5000

Registered

2021-09-01

Start date

2021-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical cancer and cervical intraepithelial neoplasia

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: (1) Women over 20 years old (2) Policyholders and insured women who have subscribed to insurance products of TAIYO LIFE INSURANCE COMPANY (3) Women who take the self-sampling hrHPV test service through the Web "PAPI'Qss" provided by GeneticLab from September 1, 2021 to August 31, 2024.

Exclusion criteria

Exclusion criteria: (1) Women who do not consent to participate (2) Male (3) Women less than 20 years old (4) Women in pregnancy (5) Women who are judged inappropriate for the test by a doctor

Design outcomes

Primary

Measure	Time frame
The detection rate of cervical intraepithelial neoplasia grade 2 (CIN 2) or worse during whole periods	—

Secondary

Measure	Time frame
Application rate for self-sampling hrHPV test through the Web Frequency of self-sampling hrHPV testing Positive rate of hrHPV tests Invalid specimens rate for testing Questionnaire survey Frequency of receiving cervical cancer screening Frequency of receiving cytology Frequency of detailed examination required Frequency of receiving detailed examination Detection rate of CIN 2 or worse per cytology Frequency of adverse events	—

Measure

Time frame

Application rate for self-sampling hrHPV test through the Web Frequency of self-sampling hrHPV testing Positive rate of hrHPV tests Invalid specimens rate for testing Questionnaire survey Frequency of receiving cervical cancer screening Frequency of receiving cytology Frequency of detailed examination required Frequency of receiving detailed examination Detection rate of CIN 2 or worse per cytology Frequency of adverse events

—

Countries

Japan

Contacts

Public ContactAkari Nagasaki

Eurofins GeneticLab Co., Ltd. Administration Department Sales Promotion Team

patho@gene-lab.com011-644-7333

Outcome results